HC Wainwright Lowers Imunon (NASDAQ:IMNN) Price Target to $12.00

Imunon (NASDAQ:IMNN) had its price objective decreased by analysts at HC Wainwright from $14.00 to $12.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Stock Down 6.4 %

Shares of IMNN stock opened at $0.78 on Monday. The business has a 50-day moving average price of $1.01 and a two-hundred day moving average price of $1.19. Imunon has a 12-month low of $0.48 and a 12-month high of $3.65. The firm has a market cap of $46.56 million, a P/E ratio of -0.44 and a beta of 2.14.

Imunon (NASDAQ:IMNN) last released its earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.04. As a group, research analysts expect that Imunon will post -1.71 EPS for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.